ERBB2 and carcinoma: These include loss of PTEN [33], predominance of the p95HER2 expression [34], mTOR/PI3K/AKT hyperactivation [35], IGF-IR overexpression [36], and in vivo conversion of HER2+ to HER2- carcinoma after neoadjuvant trastuzumab [37].